GeneDx (WGS) announced new data from the SeqFirst study, conducted with Seattle Children’s, supporting rapid exome and genome sequencing as a first-tier test for non-critical pediatric inpatients. Published in The Journal of Pediatrics, the analysis showed rapid genome testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days. The diagnostic yield remained high at over 42%, comparable to critical care settings. The study supports broader adoption to improve patient outcomes and lower healthcare costs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx says AAP recommends exome, genome sequencing as tests for children
- AAP guidance ‘another reason to believe’ in GeneDx, says Craig-Hallum
- GeneDx Holdings: Navigating Market Opportunities and Delayed Financial Impact Amid AAP Testing Guidelines Update
- Galatea Bio, Fabric Genomics partner on genetic testing for common diseases
- GeneDx Holdings Approves Key Proposals at Annual Meeting